UBS Upgrades Helicos BioSciences (HLCS) to Neutral
More News related to HLCS
- Unusual 11 Mid-Day Movers 11/11: NCST, SMI, MSN, CHLN Higher; TONE, RHIE, CLWR, STV Lower
- Helicos BioSciences (HLCS) Files $50M Shelf Registration
- Helicos BioSciences (HLCS) Announces Filing of 10-Q; Disengages in Sale of Company
- Helicos BioSciences Provides Strategic Update
- Helicos BioSciences (HLCS) Comments on Q3 Operations
More News related to Upgrades
- S&P Revises Outlook on Sirius XM (SIRI) from Stable to Positive
- DA Davidson Upgrade Lifts Shares of Ameron (AMN) by ~9%
- Sterne Agee Upgrades TrustCo Bank Corp NY (TRST) to Neutral
- optionsXpress (OXPS) Upgraded Mid-Day at BofA, Stock Adds 3% to Today's Gains
- D.A. Davidson Upgrades Columbia Sportswear (COLM) to Buy
UBS upgrades Helicos BioSciences (Nasdaq: HLCS) from Sell to Neutral.
Helicos BioSciences Corporation is a life sciences company developing genetic analysis technologies for the research, drug discovery and clinical diagnostics markets.
Related Categories
UpgradesStocks Mentioned
-0.38Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
